Revolutionizing ALS Models, Novel Biomarkers & Clinical Endpoints to Accelerate Future ALS Approvals

The FDA approvals of Amylyx’s Relyvrio and the Biogen/Ionis Pharmaceutical’s Tofersen mark an important series of firsts in ALS drug development. The first ALS drug that showed a significant slowing in both disease progression and functional decline, the first therapy to treat SOD1 genetic mutations, and the first treatment to receive accelerated approval based on NfL biomarker reduction.

With these exciting regulatory firsts, booming pharma investment, and new biotechs entering the field, the ALS drug development landscape is gaining momentum and positivity. However, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.

Capturing this, the timely 2nd Annual ALS Drug Development Summit was the only industry-focused conference dedicated to overcoming preclinical clinical challenges currently facing ALS pipelines. This was the must-attend meeting showcasing the latest breakthroughs in ALS in 2023.